Ruth Link-Gelles on Muck Rack

Ruth Link-Gelles

As seen in: Center for Disease Control and Prevention, Emerging Infectious Diseases Journal, Nature, JAMA (The Journal of the American Medical Association), JAMA Network, JAMA: Journal of the American Medical Association, Medscape, The New England Journal of Medicine, The Lancet, CDC Featured Podcasts
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruth

Contact Ruth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design

|
By Ryan Wiegand, Sean Chickery, Duck-Hye Yang, Sarah Ball Verified, Malini DeSilva, Kristin Dascomb, Stephanie A. Irving, Karthik Natarajan, Nicola P. Klein, Shaun Grannis, Toan C Ong, Elizabeth Rowley, Adam Yates, Yan Zhuang Verified, Charlene E. McEvoy, Omobosola Akinsete, Allison L. Naleway, Padma Koppolu, Ousseny Zerbo, John Hansen, Karen B. Jacobson, Lawrence Block, Thomas Duszynski, Colin Rogerson, Michelle Barron, Catia Chávez, Josephine Mak, Allison Avrich Ciesla, Monica Godfrey, Morgan Najdowski, Ruth Link-Gelles, Jennifer DeCuir, Amanda Payne, Inih J. Essien, Amber Kautz
| JAMA Network Verified
Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design Supplement 1. eTable 1. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) used to define COVID-19-like illness eTable 2. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) used to define underlying medical condition and immunocompromise status Supplement 2. Table 1.
Open in Who Shared Issue with article?

Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults

|
By Ruth Link-Gelles
| JAMA (The Journal of the American Medical Association) Verified
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults Supplement 1. eTable 1. Number of Emergency Departments, Urgent Cares, and Hospitals, by Participating VISION Study Site eTable 2. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) Used to Define COVID-19-Like Illness eTable 3. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) Used to Define eTable 4.
Open in Who Shared Issue with article?

Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025

|
By Ruth Link-Gelles, Sean Chickery, Alexander P. Webber
| CDC Featured Podcasts
Methods Methods for VE analyses in the Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION) and Investigating Respiratory Viruses in the Acutely Ill (IVY) network have been reported (4,5).
Open in Who Shared Issue with article?
See all 24 licensed articles (52 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified